1789 (1789) Fair Value & Analysis

Healthcare · Market cap HK$5.5B

1 1789 1789 · HK

PriceHK$5.11

Fair ValueHK$7.06

Upside+38.2%

Quality61/100

Watch 1789 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$5.21 – HK$8.77

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −11.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$4.79 – HK$6.96 · fair‑value band HK$5.21 – HK$8.77 · the HK$5.11 price screens below the HK$7.06 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1789 (1789) currently trades at HK$5.11, while our model-based Fair Value estimate is HK$7.06 — implying the stock looks roughly 38.2% undervalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 1789 generated revenue of HK$1.5B at a net margin of 22.9%. Revenue grew 14.4% year over year. It earns a return on equity of 12.2%. The balance sheet holds a net cash position of HK$230M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.5B

Revenue growth (YoY) +14.4%

Net margin 22.9%

Return on equity 12.2%

Free cash flow HK$316M FY2025

P/E ratio 14.6

More key figures

Operating margin 26.2%

EPS (TTM) HK$0.1400

Dividend yield 2.1%

EPS growth (YoY) +32.3%

Net cash HK$230M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1789 reported revenue of HK$1.5B in FY2025 versus HK$761M in FY2021, a compound +18.1%/yr. Reported net income was HK$339M in FY2025, compounding +38.3%/yr from FY2021.

Revenue +18.1%/yr

FY21 HK$761M

FY22 HK$1.1B

FY23 HK$1.1B

FY24 HK$1.3B

FY25 HK$1.5B

Net income +38.3%/yr

FY21 HK$92.6M

FY22 HK$205M

FY23 HK$182M

FY24 HK$274M

FY25 HK$339M

Is 1789 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	82.40 MXN	-95%
Abbott Laboratories, ABTT34	R$39.41	R$30.42	-23%
Stryker Corporation S1YK34	R$79.18	R$43.78	-45%
Medtronic plc MDT	$79.27	$73.33	-7%
Boston Scientific Corporation B1SX34	R$229.30	R$43.33	-81%
Edwards Lifesciences Corporation EW	$87.45	$41.02	-53%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1789 (1789) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$7.06 versus a price of HK$5.11 — about +38% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1789?

Our model-based fair value for 1789 is HK$7.06 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$5.11.

What is the quality score of 1789?

1789 has a Quality Score of 61/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1789 (1789)?

1789 reported trailing-twelve-month revenue of about HK$1.5B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1789?

The net profit margin of 1789 is about 22.9%, meaning it keeps roughly 22.9% of revenue as net income. Based on the latest reported figures.

Does 1789 pay a dividend?

1789 currently shows a dividend yield of about 2.07% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.